CANCER TRIALS IRELAND COMPANY LIMITED BY GUARANTEE

Their core work

Cancer Trials Ireland (formerly ICORG — Irish Clinical Oncology Research Group, as reflected in their website icorg.ie) is Ireland's national cancer clinical trials network, coordinating multi-centre oncology studies across Irish hospitals. In H2020 consortia, they contribute structured patient cohort access, clinical trial management infrastructure, and the translational bridge between laboratory research and real-world patient outcomes. Their participation in COLOSSUS focused on systems medicine approaches to metastatic colorectal cancer, applying multi-omics profiling and computational patient stratification to identify treatment-predictive molecular subtypes. For research consortia that need a validated clinical entry point in Ireland — including patient recruitment, ethical governance, and regulated trial conduct — they are the primary national gateway.

What they specialise in

How they've shifted over time

With only two projects spanning 2017–2023, the trajectory is narrow but directionally clear. Early involvement in GLIOTRAIN (2017) placed them in a brain cancer training network with no deep technical keyword footprint, suggesting a broad clinical support role rather than domain specialisation. By COLOSSUS (2018), the keyword profile sharpened considerably — colorectal cancer, RAS mutation, multi-omics, immunomics, systems medicine — indicating a deliberate move toward precision oncology with computational and molecular depth. The shift is from generalist oncology trial infrastructure toward a focused specialty in systems-based approaches to gastrointestinal cancers.

Cancer Trials Ireland is moving from broad oncology trial support toward specialised precision medicine, particularly in gastrointestinal cancers with multi-omics and molecular stratification — making them a strong fit for future consortia addressing personalised cancer treatment or companion diagnostics.

How they like to work

Cancer Trials Ireland has never coordinated an H2020 project, always participating as a partner or third party — consistent with an organisation whose value lies in clinical infrastructure rather than scientific leadership. They engage in large, multi-national consortia (32 unique partners across 11 countries from just 2 projects), which shows they integrate smoothly into complex collaborative structures. Prospective partners should expect them to contribute patient access, trial governance, and clinical validation capabilities rather than driving the research agenda.

Despite only two H2020 projects, Cancer Trials Ireland has connected with 32 unique consortium partners across 11 countries, reflecting the broad multi-site coalitions typical of European oncology research consortia. No strong geographic concentration beyond Ireland is evident, suggesting European-wide openness rather than a regional cluster focus.

What sets them apart

As Ireland's only national cancer trials network, Cancer Trials Ireland offers something that no other Irish institution replicates: a certified, multi-hospital infrastructure for recruiting and managing oncology patient cohorts at national scale. For any EU research project requiring Irish patient data, clinical validation, or regulated trial conduct in Ireland, they are effectively the sole practical partner. Their dual participation in both MSCA training networks and RIA research actions demonstrates that they can serve as both a clinical training host and an active research contributor within the same consortium.

Highlights from their portfolio

• COLOSSUS
  Their only directly funded project (EUR 200,854), addressing one of the hardest stratification problems in oncology — RAS-mutant metastatic colorectal cancer — using a full systems medicine stack including multi-omics, immunomics, and in vitro diagnostics.
• GLIOTRAIN
  Participation as a third party in an MSCA-ITN training network for glioblastoma demonstrates their ability to support doctoral researcher training within clinical oncology settings, beyond standard trial participation.